Spun out of Boston University, Abtelum Biomedical, Inc. is developing a lead hinge-stabilized, humanized-optimized antibody therapy that inhibits a novel protein target. Designated Dual Endothelin-1/signal peptide Receptor (DEspR), the project s described as exhibiting preclinical survival benefit and safety in models of pancreatic carcinomatosis and spontaneous intracerebral hemorrhage (sICH). D EspR promotes maladaptive survival of cancer stem cells underlying metastasis and of rogue activated neutrophils driving secondary brain injury in hemorrhagic stroke, actions blocked by ABTM-468. The underpnning technology is backed by four patent families all held to date by the Trustees of Boston University with the principals of Abtelum Biomedical the designated inventors
